全文获取类型
收费全文 | 65575篇 |
免费 | 19028篇 |
国内免费 | 3033篇 |
出版年
2023年 | 497篇 |
2022年 | 553篇 |
2021年 | 2012篇 |
2020年 | 3300篇 |
2019年 | 5087篇 |
2018年 | 5114篇 |
2017年 | 4972篇 |
2016年 | 5489篇 |
2015年 | 6410篇 |
2014年 | 6362篇 |
2013年 | 7117篇 |
2012年 | 5543篇 |
2011年 | 4942篇 |
2010年 | 5025篇 |
2009年 | 3618篇 |
2008年 | 2933篇 |
2007年 | 2312篇 |
2006年 | 2082篇 |
2005年 | 1799篇 |
2004年 | 1636篇 |
2003年 | 1452篇 |
2002年 | 1284篇 |
2001年 | 1110篇 |
2000年 | 925篇 |
1999年 | 767篇 |
1998年 | 411篇 |
1997年 | 390篇 |
1996年 | 363篇 |
1995年 | 321篇 |
1994年 | 331篇 |
1993年 | 238篇 |
1992年 | 394篇 |
1991年 | 347篇 |
1990年 | 292篇 |
1989年 | 266篇 |
1988年 | 226篇 |
1987年 | 177篇 |
1986年 | 172篇 |
1985年 | 181篇 |
1984年 | 152篇 |
1983年 | 113篇 |
1982年 | 99篇 |
1981年 | 57篇 |
1980年 | 60篇 |
1979年 | 76篇 |
1978年 | 69篇 |
1977年 | 58篇 |
1976年 | 68篇 |
1975年 | 63篇 |
1974年 | 75篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
1.
2.
Michael P. Gustafson Yi Lin Mary L. Maas Virginia P. Van Keulen Patrick B. Johnston Tobias Peikert Dennis A. Gastineau Allan B. Dietz 《PloS one》2015,10(3)
The development of flow cytometric biomarkers in human studies and clinical trials has been slowed by inconsistent sample processing, use of cell surface markers, and reporting of immunophenotypes. Additionally, the function(s) of distinct cell types as biomarkers cannot be accurately defined without the proper identification of homogeneous populations. As such, we developed a method for the identification and analysis of human leukocyte populations by the use of eight 10-color flow cytometric protocols in combination with novel software analyses. This method utilizes un-manipulated biological sample preparation that allows for the direct quantitation of leukocytes and non-overlapping immunophenotypes. We specifically designed myeloid protocols that enable us to define distinct phenotypes that include mature monocytes, granulocytes, circulating dendritic cells, immature myeloid cells, and myeloid derived suppressor cells (MDSCs). We also identified CD123 as an additional distinguishing marker for the phenotypic characterization of immature LIN-CD33+HLA-DR- MDSCs. Our approach permits the comprehensive analysis of all peripheral blood leukocytes and yields data that is highly amenable for standardization across inter-laboratory comparisons for human studies. 相似文献
3.
Detection and genotyping of group A rotaviruses isolated from sewage samples in Monastir,Tunisia between April 2007 and April 2010 下载免费PDF全文
4.
5.
6.
7.
8.
9.
Chiao-Fang Teng Wen-Chuan Hsieh Han-Chieh Wu Yih-Jyh Lin Hung-Wen Tsai Wenya Huang Ih-Jen Su 《PloS one》2015,10(4)
Hepatitis B virus (HBV) pre-S2 mutant can induce hepatocellular carcinoma (HCC) via the induction of endoplasmic reticulum stress to activate mammalian target of rapamycin (MTOR) signaling. The association of metabolic syndrome with HBV-related HCC raises the possibility that pre-S2 mutant-induced MTOR activation may drive the development of metabolic disorders to promote tumorigenesis in chronic HBV infection. To address this issue, glucose metabolism and gene expression profiles were analyzed in transgenic mice livers harboring pre-S2 mutant and in an in vitro culture system. The pre-S2 mutant transgenic HCCs showed glycogen depletion. The pre-S2 mutant initiated an MTOR-dependent glycolytic pathway, involving the eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1), Yin Yang 1 (YY1), and myelocytomatosis oncogene (MYC) to activate the solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1), contributing to aberrant glucose uptake and lactate production at the advanced stage of pre-S2 mutant transgenic tumorigenesis. Such a glycolysis-associated MTOR signal cascade was validated in human HBV-related HCC tissues and shown to mediate the inhibitory effect of a model of combined resveratrol and silymarin product on tumor growth. Our results provide the mechanism of pre-S2 mutant-induced MTOR activation in the metabolic switch in HBV tumorigenesis. Chemoprevention can be designed along this line to prevent HCC development in high-risk HBV carriers. 相似文献
10.